Bradley Fehrenbach, MD, MBA, presented “Industry Perspective: Illuccix® for 68Ga-PSMA-11 PET Imaging of Prostate Cancer” at the 34th Annual International Prostate Cancer Update in Vail, Colorado, on February 14, 2024.
How to cite: Fehrenbach, Bradley. “Industry Perspective: Illuccix® for 68Ga-PSMA-11 PET Imaging of Prostate Cancer.” February 14, 2024. Accessed May 2024. https://grandroundsinurology.com/industry-perspective-illuccix-for-gallium-68-psma-11-pet-imaging-of-prostate-cancer
Industry Perspective: Illuccix® for 68Ga-PSMA-11 PET Imaging of Prostate Cancer – Summary
In this Industry Perspective, supported by Telix Pharmaceuticals, Bradley Fehrenbach, MD, MBA, presents Illuccix® for 68Ga-PSMA-11 PET imaging of prostate cancer. Dr. Fehrenbach begins by listing the FDA-approved indications for the use of Illuccix® during initial prostate cancer staging, after biochemical recurrence of prostate cancer, and before treating mCRPC.
Dr. Fehrenbach reviews data supporting the high diagnostic value, reproducibility, and accuracy of Illuccix®. He presents studies demonstrating its high true-positive rate, its ability to detect clinically significant disease when the patient’s PSA level is as low as 0.02 ng/ml, and high inter-reader agreement.
Dr. Fehrenback concludes by listing the clinical benefits and practical accessibility of 68Ga radiotracers for PET scans. At the conclusion of his presentation, he briefly answers questions posed to him by the Program Chair.
